INSMED INC (INSM) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:INSM • US4576693075

148.43 USD
-0.12 (-0.08%)
At close: Feb 11, 2026
147.171 USD
-1.26 (-0.85%)
After Hours: 2/11/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall INSM gets a fundamental rating of 3 out of 10. We evaluated INSM against 523 industry peers in the Biotechnology industry. INSM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. INSM is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • INSM had negative earnings in the past year.
  • In the past year INSM has reported a negative cash flow from operations.
  • In the past 5 years INSM always reported negative net income.
  • INSM had a negative operating cash flow in each of the past 5 years.
INSM Yearly Net Income VS EBIT VS OCF VS FCFINSM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M -800M

1.2 Ratios

  • INSM's Return On Assets of -50.15% is in line compared to the rest of the industry. INSM outperforms 50.29% of its industry peers.
  • INSM has a worse Return On Equity (-125.20%) than 60.61% of its industry peers.
Industry RankSector Rank
ROA -50.15%
ROE -125.2%
ROIC N/A
ROA(3y)-43.52%
ROA(5y)-40.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INSM Yearly ROA, ROE, ROICINSM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

  • INSM's Gross Margin of 76.54% is amongst the best of the industry. INSM outperforms 84.32% of its industry peers.
  • In the last couple of years the Gross Margin of INSM has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for INSM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.05%
GM growth 5Y-1.46%
INSM Yearly Profit, Operating, Gross MarginsINSM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • INSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, INSM has more shares outstanding
  • Compared to 5 years ago, INSM has more shares outstanding
  • INSM has a better debt/assets ratio than last year.
INSM Yearly Shares OutstandingINSM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
INSM Yearly Total Debt VS Total AssetsINSM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • INSM has an Altman-Z score of 9.85. This indicates that INSM is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 9.85, INSM belongs to the top of the industry, outperforming 81.45% of the companies in the same industry.
  • A Debt/Equity ratio of 0.77 indicates that INSM is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.77, INSM is not doing good in the industry: 71.89% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF N/A
Altman-Z 9.85
ROIC/WACCN/A
WACC12.23%
INSM Yearly LT Debt VS Equity VS FCFINSM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

  • A Current Ratio of 4.63 indicates that INSM has no problem at all paying its short term obligations.
  • With a Current ratio value of 4.63, INSM perfoms like the industry average, outperforming 53.54% of the companies in the same industry.
  • INSM has a Quick Ratio of 4.34. This indicates that INSM is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of INSM (4.34) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.63
Quick Ratio 4.34
INSM Yearly Current Assets VS Current LiabilitesINSM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • INSM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -11.53%.
  • Looking at the last year, INSM shows a very strong growth in Revenue. The Revenue has grown by 30.34%.
  • The Revenue has been growing by 21.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-11.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.8%
Revenue 1Y (TTM)30.34%
Revenue growth 3Y24.49%
Revenue growth 5Y21.65%
Sales Q2Q%52.36%

3.2 Future

  • Based on estimates for the next years, INSM will show a very strong growth in Earnings Per Share. The EPS will grow by 26.44% on average per year.
  • Based on estimates for the next years, INSM will show a very strong growth in Revenue. The Revenue will grow by 67.90% on average per year.
EPS Next Y-9.24%
EPS Next 2Y20.55%
EPS Next 3Y24.84%
EPS Next 5Y26.44%
Revenue Next Year55.07%
Revenue Next 2Y93.53%
Revenue Next 3Y87.53%
Revenue Next 5Y67.9%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INSM Yearly Revenue VS EstimatesINSM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B 8B 10B
INSM Yearly EPS VS EstimatesINSM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for INSM. In the last year negative earnings were reported.
  • Also next year INSM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INSM Price Earnings VS Forward Price EarningsINSM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INSM Per share dataINSM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

  • INSM's earnings are expected to grow with 24.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.55%
EPS Next 3Y24.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • INSM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INSMED INC

NASDAQ:INSM (2/11/2026, 8:00:02 PM)

After market: 147.171 -1.26 (-0.85%)

148.43

-0.12 (-0.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30
Earnings (Next)02-18
Inst Owners99.83%
Inst Owner Change0.25%
Ins Owners0.59%
Ins Owner Change-12.67%
Market Cap31.66B
Revenue(TTM)447.02M
Net Income(TTM)-1.18B
Analysts85.6
Price Target219.19 (47.67%)
Short Float %5.64%
Short Ratio3.64
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-28.48%
Min EPS beat(2)-28.87%
Max EPS beat(2)-28.09%
EPS beat(4)0
Avg EPS beat(4)-18.15%
Min EPS beat(4)-28.87%
Max EPS beat(4)-4.46%
EPS beat(8)1
Avg EPS beat(8)-14.89%
EPS beat(12)2
Avg EPS beat(12)-15.58%
EPS beat(16)4
Avg EPS beat(16)-11.73%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)1.43%
Max Revenue beat(2)20.71%
Revenue beat(4)2
Avg Revenue beat(4)5.14%
Min Revenue beat(4)-1.17%
Max Revenue beat(4)20.71%
Revenue beat(8)3
Avg Revenue beat(8)1.76%
Revenue beat(12)4
Avg Revenue beat(12)1.09%
Revenue beat(16)6
Avg Revenue beat(16)1.62%
PT rev (1m)-0.05%
PT rev (3m)23.03%
EPS NQ rev (1m)15.27%
EPS NQ rev (3m)15.04%
EPS NY rev (1m)3.59%
EPS NY rev (3m)-0.87%
Revenue NQ rev (1m)28.58%
Revenue NQ rev (3m)29.02%
Revenue NY rev (1m)9.44%
Revenue NY rev (3m)12.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 70.81
P/FCF N/A
P/OCF N/A
P/B 33.48
P/tB 43.67
EV/EBITDA N/A
EPS(TTM)-6.19
EYN/A
EPS(NY)-3.06
Fwd EYN/A
FCF(TTM)-4.25
FCFYN/A
OCF(TTM)-4.14
OCFYN/A
SpS2.1
BVpS4.43
TBVpS3.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.15%
ROE -125.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.54%
FCFM N/A
ROA(3y)-43.52%
ROA(5y)-40.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.05%
GM growth 5Y-1.46%
F-Score3
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 139.18%
Cap/Sales 5.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.63
Quick Ratio 4.34
Altman-Z 9.85
F-Score3
WACC12.23%
ROIC/WACCN/A
Cap/Depr(3y)113.37%
Cap/Depr(5y)86.53%
Cap/Sales(3y)4.8%
Cap/Sales(5y)4.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.8%
EPS Next Y-9.24%
EPS Next 2Y20.55%
EPS Next 3Y24.84%
EPS Next 5Y26.44%
Revenue 1Y (TTM)30.34%
Revenue growth 3Y24.49%
Revenue growth 5Y21.65%
Sales Q2Q%52.36%
Revenue Next Year55.07%
Revenue Next 2Y93.53%
Revenue Next 3Y87.53%
Revenue Next 5Y67.9%
EBIT growth 1Y-40.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-34.1%
EBIT Next 3Y23.8%
EBIT Next 5YN/A
FCF growth 1Y-72.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-73.7%
OCF growth 3YN/A
OCF growth 5YN/A

INSMED INC / INSM FAQ

Can you provide the ChartMill fundamental rating for INSMED INC?

ChartMill assigns a fundamental rating of 3 / 10 to INSM.


Can you provide the valuation status for INSMED INC?

ChartMill assigns a valuation rating of 1 / 10 to INSMED INC (INSM). This can be considered as Overvalued.


How profitable is INSMED INC (INSM) stock?

INSMED INC (INSM) has a profitability rating of 1 / 10.


What is the financial health of INSMED INC (INSM) stock?

The financial health rating of INSMED INC (INSM) is 5 / 10.